Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 12;11(2):235.
doi: 10.3390/healthcare11020235.

Prevalence of Precancerous Cervical Lesions among Nonvaccinated Kazakhstani Women: The National Tertiary Care Hospital Screening Data (2018)

Affiliations

Prevalence of Precancerous Cervical Lesions among Nonvaccinated Kazakhstani Women: The National Tertiary Care Hospital Screening Data (2018)

Balkenzhe Imankulova et al. Healthcare (Basel). .

Abstract

Objective: At the present time, cervical cancer remains the fourth most prevalent cancer among women worldwide. Most cervical cancer cases are attributed to high-risk human papillomavirus (HPV) infection. Because the natural history of cervical cancer takes decades, the disease could be prevented if premalignant conditions are identified and appropriately managed. The aim of this study is to identify the prevalence of precancerous lesions among non-vaccinated women attending the national tertiary care hospital in Kazakhstan.

Methods: This was a retrospective study of the cervical cancer screening database (2018) from the national tertiary care hospital in Kazakhstan. Records of 6682 patients, who had cervical cytology tests by Papanicolaou (Pap test), were analyzed. Out of the revised cases, 249 patients had abnormal cervical cytology reports. The Pap test was performed using liquid-based cytology (LBC). The data were analyzed using the statistical software STATA 16. A p-value of less than 0.05 was considered statistically significant.

Results: In this retrospective analysis of 6682 patients' records, we found 3.73% (249 patients) out of all Pap tests performed in 2018 were abnormal. The prevalence of high-grade squamous intraepithelial lesion (HSIL) was high at 19.28%, and the proportion of atypical squamous cells of undetermined significance (ASCUS) and atypical squamous cells (ASCs-H) was 18.47%, while low-grade squamous intraepithelial lesion (LSIL) were identified in 62.25% of the cases. Almost 25% of the women included in the study had concurrent lower and upper genital tract infections.

Conclusion: Although the overall rate of abnormal Pap test results was not high, the study shows the elevated prevalence of HSIL. It calls the attention of local policymakers and gynecology specialists and requires immediate actions to improve the prophylactic measures to decrease morbidity and mortality from cervical cancer in Kazakhstan.

Keywords: CIN; HSIL; LSIL; cervical cancer; precancerous cervical lesions.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Prevalence of precancerous cervical lesions among the study participants.

Similar articles

Cited by

References

    1. Canfell K. Towards the global elimination of cervical cancer. Papillomavirus Res. 2019;8:100170. doi: 10.1016/j.pvr.2019.100170. - DOI - PMC - PubMed
    1. Arbyn M., Weiderpass E., Bruni L., de Sanjosé S., Saraiya M., Ferlay J., Bray F. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob. Health. 2020;8:e191–e203. doi: 10.1016/S2214-109X(19)30482-6. - DOI - PMC - PubMed
    1. D’Oria O., Corrado G., Laganà A.S., Chiantera V., Vizza E., Giannini A. New Advances in Cervical Cancer: From Bench to Bedside. Int. J. Environ. Res. Public Health. 2022;19:7094. doi: 10.3390/ijerph19127094. - DOI - PMC - PubMed
    1. Bogani G., Di Donato V., Scambia G., Raspagliesi F., Chiantera V., Sozzi G., Golia D’Augè T., Muzii L., Benedetti Panici P., D’Oria O., et al. Radical Hysterectomy for Early Stage Cervical Cancer. Int. J. Environ. Res. Public Health. 2022;19:11641. doi: 10.3390/ijerph191811641. - DOI - PMC - PubMed
    1. Giannini A., Bogani G., Vizza E., Chiantera V., Laganà A.S., Muzii L., Salerno M.G., Caserta D., D’Oria O. Advances on Prevention and Screening of Gynecologic Tumors: Are We Stepping Forward? Healthcare. 2022;10:1605. doi: 10.3390/healthcare10091605. - DOI - PMC - PubMed